Wagner Bowman Management Corp cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,078 shares of the company’s stock after selling 227 shares during the period. Wagner Bowman Management Corp’s holdings in Eli Lilly and were worth $1,240,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in LLY. BlackRock Inc. increased its position in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in shares of Eli Lilly and during the first quarter valued at $161,084,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its stake in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares during the period. Institutional investors own 75.59% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) traded down 0.05% during midday trading on Wednesday, reaching $81.67. 720,136 shares of the company traded hands. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The firm has a 50 day moving average of $82.77 and a 200-day moving average of $81.92. The stock has a market capitalization of $86.16 billion, a price-to-earnings ratio of 35.34 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 EPS. Analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.55%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.
WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/08/16/eli-lilly-and-company-lly-shares-sold-by-wagner-bowman-management-corp.html.
Several equities research analysts have recently weighed in on LLY shares. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a research report on Tuesday, May 16th. Jefferies Group LLC restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. Citigroup Inc. raised their price objective on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.